NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Blank C
AD Scientific Index 2024
Others
Netherlands Cancer Institute - / Netherlands
Nederlands Kanker Instituut
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Blank C's MOST POPULAR ARTICLES
1-)
Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015 51602015
2-)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial A Hauschild, JJ Grob, LV Demidov, T Jouary, R Gutzmer, M Millward, ... The Lancet 380 (9839), 358-365, 2012 32552012
3-)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ... Science 350 (6257), 207-211, 2015 22842015
4-)
Adjuvant pembrolizumab versus placebo in resected stage III melanomaAMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ...New England Journal of Medicine 378 (19), 1789-1801, 201817882018
5-)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialA Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...The lancet oncology 16 (8), 908-918, 201517622015
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept